Finance ForgeBETA
Crear cuenta gratis
1)Empresas2)Rankings3)Iniciar sesión
Finance Forge Terminal v1.49.5
PrivacidadTérminosCookiesAviso Legal
● Connected
VRTX US Equity
VERTEX PHARMACEUTICALS INC / MA
510.08USD▲ 1.36%
Healthcare
Biotechnology
96)Comparar97)Tesis →
Market Cap
$129.3B
Shares Outstanding
253M
— Annual —FY2025
Revenue
$12.0B
Gross Margin
86.2%
Operating Margin
34.8%
Net Margin
32.9%
FCF Margin
26.6%
ROE
21.2%
ROCE
19.2%
Current Ratio
2.9
FCF / Share
12.6
Book Value / Share
73.64
VRTX US Equity
510.08USD▲ 1.36%
Tesis →

VERTEX PHARMACEUTICALS INC / MA (VRTX): análisis fundamental y valoración

VERTEX PHARMACEUTICALS INC / MA cotiza a 510.08 USD y tiene una capitalización bursátil de $129.3B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud

Price History
Loading...
Perfil
BolsaNasdaqPaísUnited StatesEmpleados6,400Beta0.32Web↗ www.vrtx.com

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta t…

Múltiplos de Valoración
P/E (Annual)
32.7×
P/E (TTM)
—
P/FCF (Annual)
40.5×
P/FCF (TTM)
—
EV/EBITDA
—
EV/Revenue
—
P/Sales
10.8×
P/Book
6.9×
Rentabilidad (Último Anual)
Gross Margin
86.2%
Operating Margin
34.8%
Net Margin
32.9%
FCF Margin
26.6%
ROE
21.2%
ROCE
19.2%
ROA
15.4%
Effective Tax Rate
14.9%
Métricas TTM
Revenue TTM
—
Gross Profit TTM
—
Operating Income TTM
—
Net Income TTM
—
FCF TTM
—
EPS TTM
—
Quarters Used
—
TTM Period
—
Solidez del Balance
Net Debt
—
Net Debt / EBITDA
—
Debt / Equity
—
Current Ratio
2.9
Interest Coverage
732.2×
Working Capital
$7.3B
Book Value / Share
73.64
Net Debt / Share
—
Crecimiento (YoY)
Revenue YoY
+8.9%
Net Income YoY
+838.1%
FCF YoY
+504.1%
EPS Diluted YoY
+836.5%
Retorno al Accionista
Dividend Yield
—
Payout Ratio
—
FCF / Share
12.6
CapEx % Revenue
3.6%
Rev / Employee
2M
Próximos Eventos
Historial EPS
Periodo2026-112026-082026-052026-02
Real—$4.73$4.47$5.03
Estimado$-0.74$4.75$4.31$5.15
Sorpresa—-0.4%+3.7%-2.3%
Empresas similares
Smart Money
vs Sector: Healthcare (1130 empresas)
MétricaVRTXMediana SectorΔ
Gross Margin86.2%57.0%+29.2%
Operating Margin34.8%-38.6%+73.4%
Net Margin32.9%-33.6%+66.5%
FCF Margin26.6%-13.9%+40.5%
ROE21.2%-40.4%+61.6%
ROA15.4%-32.0%+47.4%
Current Ratio2.902.84+0.06
Debt / Equity—0.28—
Scoring Fundamental
Piotroski F-Score
5/ 8Moderado
✓F1ROA positivo (rentabilidad activos)
✓F2Flujo caja operativo positivo
✓F3ROA mejora vs año anterior
✗F4Calidad de beneficios (OCF > ROA)
✗F5Apalancamiento baja
✓F6Liquidez mejora (current ratio)
✗F7Sin dilución accionarial
✓F8Margen bruto mejora
✗F9Rotación activos mejora
Altman Z-ScoreZona Segura
13.21
x1_working_capital0.286
x2_retained_earnings0.529
x3_ebit0.163
x4_market_equity18.530
x5_sales0.468
>2.99 segura · 1.81–2.99 gris · <1.81 riesgo
Capital Allocation
6/ 8Sólida
✓FCF+Free cash flow positivo
✓FCFmMargen FCF > 10%
✓DilucSin dilución significativa (< 2%/año en 3 años)
✓Rev↑Revenue CAGR 3 años > 5%
✓ROCERetorno sobre capital empleado > 10%
✗DeudaDeuda neta/EBITDA < 3× (o posición de caja neta)
✗Mg↑Margen operativo ≥ hace 2-3 años (tolerancia -2pp)
✓Inv.R&D + Capex > 3% de revenue (reinversión en el negocio)
Histórico Piotroski F-Score
Histórico de Múltiplos